Development of prognostic and predictive biomarkers to aid treatment of lung cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1074035

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Early Career Fellowships

Funding Amount: $188,226.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Chemotherapy

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

gene expression | genetics | lung cancer | methylation | predictive | prognostic markers

Related Links